Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory ...

Eli Lilly has lined up another deal in the radiopharmaceutical ... is a “largely unexplored” class for radiopharma. The San Diego-based biotech is tasked by Lilly with generating a pipeline ...

Every month, roughly 100,000 people buy Zepbound directly from Eli Lilly through its website. "It's about the size of a small ...

Eli Lilly has acquired Organovo’s lead asset ... $9 million upfront plus another $1 million after 15 months to the San Diego biotech, according to Securities and Exchange Commission (SEC ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE ... approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s ...

What To Know: San Diego-based biotechnology company Organovo announced that Eli Lilly will acquire its FXR program, including lead asset FXR314, aimed at treating inflammatory bowel disease.

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE ... on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire ...